Compare TMDX & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMDX | VERA |
|---|---|---|
| Founded | 1998 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.0B |
| IPO Year | 2019 | 2021 |
| Metric | TMDX | VERA |
|---|---|---|
| Price | $83.33 | $32.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | ★ $148.22 | $81.30 |
| AVG Volume (30 Days) | 937.7K | ★ 1.9M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 382.18 | N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $605,494,000.00 | N/A |
| Revenue This Year | $24.25 | N/A |
| Revenue Next Year | $18.75 | $472.48 |
| P/E Ratio | $131.49 | ★ N/A |
| Revenue Growth | ★ 37.13 | N/A |
| 52 Week Low | $60.11 | $19.28 |
| 52 Week High | $156.00 | $56.05 |
| Indicator | TMDX | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 58.69 | 36.82 |
| Support Level | $66.18 | $30.59 |
| Resistance Level | $140.79 | $42.77 |
| Average True Range (ATR) | 4.14 | 1.73 |
| MACD | 0.63 | -0.64 |
| Stochastic Oscillator | 79.36 | 26.12 |
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.